2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 999

Development of an Affimab Engineered to Simultaneously Target IL-6 and Tnfα for Therapeutic Use in Rheumatoid Arthritis

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1706

Development of an Online Lupus Self-Management Program Based on the Transtheoretical Model of Change

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1559

Development of Lymphoma in Patients with Sjogren’s Syndrome

Sjögren's Syndrome – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1368

Diabetes Mellitus Is Not a Risk Factor for Knee Osteoarthritis, a Systematic Review and Meta-Analysis

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1229

Diagnosing Prosthetic Joint Infections in Patients with Inflammatory Arthritis

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1735

Diagnostic Accuracy of MR Angiography in a Cohort with Systemic Sclerosis Compared to Other Rheumatic Diseases with Acral Hypoperfusion

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1569

Diagnostic Performance of Labial Salivary Gland Biosy, Serological and Clinical Data in Sjogrens Syndrome. in Argentinian Multicenter

Sjögren's Syndrome – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1441

Diagnostic Performances of Antibodies Against Carbamylated Proteins in US Based Populations with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1310

Diagnostic Utility of Myositis Antibodies in Patients with Interstitial Lung Disease and Suspected Underlying Connective Tissue Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1132

Diet Modification for Gout Patients: Effects on Gout Attacks and Risk Factors for Metabolic Syndrome

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1695

Differences between Early and Adult-Onset Systemic Lupus Erythematosus in Cohort of Argentinian Patients

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1407

Differences in the Measurement Properties of the Patient-Reported Outcomes Measurement Information System Physical Function Short-Form 10a Among Racial/Ethnic Minorities with Rheumatoid Arthritis

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1035

Different Cartilage-Bone Unit in Patients with Primary Osteoarthritis and Secondary Osteoarthritis Caused By Rheumatoid Arthritis

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1442

Differential Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry and a Universal Metabolome Standard Reveals a Metabolome Profile with Consistent Accuracy for Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1059

Differentially-Utilized Transcription Factors and Enhancers in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes

Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].